MLchartDataset catalogue

devimistat

Term · Oncology and biomedicine · MLC-T-ONC-013005

A racemic mixture of the enantiomers of a synthetic alpha-lipoic lipoic acid analogue with potential chemopreventive and antineoplastic activities. Although the exact mechanism of action is unknown, devimistat has been shown to inhibit metabolic and regulatory processes required for cell growth in solid tumors. Both enantiomers in the racemic mixture exhibit antineoplastic activity.

Table 1. Record
IdentifierMLC-T-ONC-013005
FieldOncology and biomedicine
Synonymsalpha-lipoic acid analogue CPI-613
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-013005",
  "term": "devimistat",
  "field": "Oncology and biomedicine",
  "definition": "A racemic mixture of the enantiomers of a synthetic alpha-lipoic lipoic acid analogue with potential chemopreventive and antineoplastic activities. Although the exact mechanism of action is unknown, devimistat has been shown to inhibit metabolic and regulatory processes required for cell growth in solid tumors. Both enantiomers in the racemic mixture exhibit antineoplastic activity.",
  "synonyms": [
    "alpha-lipoic acid analogue CPI-613"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/devimistat/"
}

Record 5,887 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.